Navigation Links
Pharsight to Present on Its Vision for Modeling and Simulation Software at PAGE Annual Meeting

Dr. Robert Leary Will Discuss Computational Methods for Model Evaluation;

Dr. Mike Dunlavey Will Present Simplified Programming Approaches of

Population Model User Interfaces

MOUNTAIN VIEW, Calif., June 12 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Pharsight software development experts will deliver two poster presentations at the Population Approach Group in Europe (PAGE) 17th Annual Meeting in Marseille, France from June 18-20, 2008. Robert Leary, Ph.D., fellow, Pharsight Research and Development Group, will present work on computational methods for model evaluation. Mike Dunlavey, Ph.D., fellow, Pharsight Research and Development Group, will present new approaches on simplified programming of population model user interfaces.

These poster sessions will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Pharsight's two presentations are:

-- June 18: Simplified Programming of Population Model User Interfaces.

Dr. Dunlavey will present a differential execution algorithm that

allows a "painting" paradigm (called Dynamic Dialogs) as an alternative

to event-based programming. This programming paradigm simplifies

implementation of software products with complex graphical displays and

user interface requirements.

-- June 19: Nonparametric Analogs to POSTHOC Estimates for Exploratory

Data Analysis. Dr. Leary will present a nonparametric model evaluation

method to complement commonly used approaches for exploratory data

analysis of possible covariate relationships. This work builds on

applied research presented by industry colleagues at past PAGE

conferences and on Dr. Leary's earlier work in the area of nonlinear

mixed effects (NLME) analysis.

"The development of advanced computational tools and next generation programming languages are integral to the continued growth of model-based drug development," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "We continue to develop technology to remain on the cutting edge of the industry and to create solutions that meet our customers' specific needs. Pharsight looks forward to presenting on specific elements of our vision for the future of model-based drug development, and is proud to again have such a wide presence at PAGE this year."

Additional information about PAGE can be found at

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting
2. Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
3. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
4. Pharsight Strengthens Senior Management Team
5. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
6. Pharsight Signs New Diabetes Meta-Database Customer
7. Pharsight to Present at eClinical Forum
8. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
9. FDA and Pharsight Continue to Collaborate Under CRADA
10. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
11. Pharsight Achieves $7.3 Million in Quarterly Revenue
Post Your Comments:
(Date:12/1/2015)... N.C. (PRWEB) , ... December 01, 2015 , ... The ... to drive awareness and funds for Multiple System Atrophy (MSA) research, timed today to ... Atrophy takes many things from patients including their ability to work and be productive, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Royal River ... a new study that found post-menopausal women who took the nutritional supplement creatine, along ... women who trained but did not take creatine. , The report is part of ...
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville has ... the only hospital in the region providing what is known as the world’s ... patients were revealed recently at a medical conference and published in The New ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
(Date:12/1/2015)... 1, 2015 Building on its 25-year ... Johnson (NYSE: JNJ ) today announced four ... to significantly reduce the burden of HIV incidence, ... percent of new HIV infections among adolescents in ... Day, these new initiatives include collaborations with the ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
Breaking Medicine Technology: